Effect of pH, polymer concentration and molecular weight on the physical state properties of tolfenamic acid

References

• Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 1997;86:1–12
   PubMed Web of Science ®Google Scholar
• Jondhale S, Bhise S, Pore Y. Physicochemical investigations and stability studies of amorphous gliclazide. AAPS PharmSciTech 2012;13:448–459
   PubMed Web of Science ®Google Scholar
• Sun Y, Zhu L, Wu T, et al. Stability of amorphous pharmaceutical solids: crystal growth mechanisms and effect of polymer additives. AAPS J 2012;14:380–388
   PubMed Web of Science ®Google Scholar
• Van Eerdenbrugh B, Taylor LS. Small scale screening to determine the ability of different polymers to inhibit drug crystallization upon rapid solvent evaporation. Mol Pharm 2010;7:1328–1337
   PubMedGoogle Scholar
• Trasi NS, Taylor LS. Effect of polymers on nucleation and crystal growth of amorphous acetaminophen. CrstEngComm 2012;14:5188–5197
   Web of Science ®Google Scholar
• Shah B, Kakumanu VK, Bansal AK. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci 2006;95:1641–1665
   PubMed Web of Science ®Google Scholar
• Thybo P, Kristensen J, Hovgaard L. Characterization and physical stability of tolfenamic Acid-PVP K30 solid dispersions. Pharm Dev Technol 2007;12:43–53
   PubMed Web of Science ®Google Scholar
• O’Neil MJ, ed. Monograph on tolfenamic acid, The Merck Index. 15th ed. Rahway, NJ: Merck & Co Inc., Electronic version; 2013
   Google Scholar
• British Pharmacopoeia. Monograph on tolfenamic acid. London: Her Majesty’s Stationary Office, Electronic version; 2013
   Google Scholar
• Sweetman SC, ed. Martindale: the complete drug reference. 36th ed. London: Pharmaceutical Press; 2009:130
   Google Scholar
• British National Formulary 61. London: BMJ Group and RPS Publishing; 2011:273–274
   Google Scholar
• Liu X, Abdelrahim M, Abudayyeh A, et al. The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression. Mol Cancer Ther 2009;8:1207–1217
   PubMed Web of Science ®Google Scholar
• Colon J, Basha MR, Madero-Visbal R, et al. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs 2011;29:41–51
   PubMed Web of Science ®Google Scholar
• Eslin D, Sankpal UT, Lee C, et al. Tolfenamic acid inhibits neuroblastoma cell proliferation and induces apoptosis: a novel therapeutic agent for neuroblastoma. Mol Carcinog 2011. [Epub ahead of print]. doi:10.1002/mc.21866
   Google Scholar
• Kim JH, Jung JY, Shim JH, et al. Apoptotic effect of tolfenamic acid in kb human oral cancer cells: possible involvement of the p38 MAPK pathway. J Clin Biochem Nutr 2010;47:74–80
   PubMed Web of Science ®Google Scholar
• Shim JH, Shin JA, Jung JY, et al. Chemopreventive effect of tolfenamic acid on KB human cervical cancer cells and tumor xenograft by downregulating specificity protein 1. Eur J Cancer Prev 2011;20:102–111
   PubMed Web of Science ®Google Scholar
• Kang SU, Shin YS, Hwang HS, et al. Tolfenamic acid induces apoptosis and growth inhibition in head and neck cancer: involvement of NAG-1 expression. PLoS One 2012;7:e34988
   PubMed Web of Science ®Google Scholar
• Adwan LI, Basha R, Abdelrahim M, et al. Tolfenamic acid interrupts the de novo synthesis of the β-amyloid precursor protein and lowers amyloid beta via a transcriptional pathway. Curr Alzheimer Res 2011;8:385–392
   PubMed Web of Science ®Google Scholar
• Subaiea GM, Alansi BH, Serra DA, et al. The ability of tolfenamic acid to penetrate the brain: a model for testing the brain disposition of candidate Alzheimer’s drugs using multiple platforms. Curr Alzheimer Res 2011;8:860–867
   PubMed Web of Science ®Google Scholar
• Andrews PC, Ferrero RL, Junk PC, et al. Bismuth(III) complexes derived from non-steroidal anti-inflammatory drugs and their activity against Helicobacter pylori. Dalton Trans 2010;39:2861–2868
   PubMed Web of Science ®Google Scholar
• Rozou S, Antoniadou-Vyza E. An improved HPLC method overcoming Beer’s law deviations arising from supramolecular interactions in tolfenamic acid and cyclodextrins complexes. J Pharm Biomed Anal 1998;18:899–905
   PubMed Web of Science ®Google Scholar
• Rozou S, Michaleas S, Antoniadou-Vyza E. Supramolecular interactions between tolfenamic acid and various cyclodextrins: effects of complexation on physicochemical and spectroscopic data. Pharm Pharmacol Commun 1999;5:79–84
   Google Scholar
• Bergström CA, Wassvik CM, Johansson K, Hubatsch I. Poorly soluble marketed drugs display solvation limited solubility. J Med Chem 2007;50:5858–5862
   PubMed Web of Science ®Google Scholar
• Pentikainen PJ, Neuvonen PJ, Backman C. Human pharmacokinetics of tolfenamic acid, a new anti-inflammatory agent. Eur J Clin Pharmacol 1981;19:359–365
   PubMed Web of Science ®Google Scholar
• Pedersen SB. Biopharmaceutical aspects of tolfenamic acid. Pharmacol Toxicol 1994;75:22–32
   PubMedGoogle Scholar
• Moffat AC, Osselton MD, Widdop B, ed. Clarke’s analysis of drugs and poisons. 4th ed. London: Pharmaceutical Press; 2011:2167
   Google Scholar
• Rowe RC, Sheskey PJ, Quinn ME. Handbook of pharmaceutical excipients. 4th ed. London: Pharmaceutical Press; 2009:110–114
   Google Scholar
• Andersen KV, Larsen S, Alhede B, et al. Characterization of two polymorphic forms of tolfenamic acid, N-(2 methyl-3-chlorophenyl)anthranilic acid: their crystal structures and relative stabilities. J Chem Soc Perkin Trans 1989;2:1443–1447
   Google Scholar
• Mattei A, Li T. Polymorph formation and nucleation mechanism of tolfenamic acid in solution: an investigation of pre-nucleation solute association. Pharm Res 2012;29:460–470
   PubMed Web of Science ®Google Scholar
• Surov AO, Szterner P, Zielenkiewicz W, Perlovich GL. Thermodynamic and structural study of tolfenamic acid polymorphs. J Pharm Biomed Anal 2009;50:831–840
   PubMed Web of Science ®Google Scholar
• Sarsfield BA, Davidovich M, Desikan S, et al. Powder X-ray diffraction detection of crystalline phases in amorphous pharmaceuticals. JCPDS-ICDD 2006;49:322–327
   Google Scholar
• Gilpin RK, Zhou W. Infrared studies of the polymorphic states of the fenamates. J Pharm Biomed Anal 2005;37:509–515
   PubMed Web of Science ®Google Scholar
• Lopez-Mejaias V, Kampf JW, Matzger AJ. Polymer-induced heteronucleation of tolfenamic acid: structural investigation of a pentamorph. J Am Chem Soc 2009;131:4554–4555
   PubMed Web of Science ®Google Scholar
• Baird JA, Van Eerdenbrugh B, Taylor LS. A classification system to assess the crystallization tendency of organic molecules from undercooled melts. J Pharm Sci 2010;99:3787–3806
   PubMed Web of Science ®Google Scholar
• Ahmed S, Sheraz MA, Rehman IU. Studies on tolfenamic acid-chitosan intermolecular interactions: effect of pH, polymer concentration and molecular weight. AAPS PharmSciTech 2013;14:870–879
   PubMed Web of Science ®Google Scholar
• Istanbullu H, Ahmed S, Sheraz MA, Rehman IU. Development and characterization of novel polyurethane films impregnated with tolfenamic acid for therapeutic applications. Biomed Res Int 2013;2013:178973 (1--8)
   Web of Science ®Google Scholar
• Gong K, Darr JA, Rehman IU. Supercritical fluid assisted impregnation of indomethacin into chitosan thermosets for controlled release applications. Int J Pharm 2006;315:93–98
   PubMed Web of Science ®Google Scholar
• Gong K, Rehman IU, Darr JA. Characterization and drug release investigation of amorphous drug-hydroxypropyl methylcellulose composites made via supercritical carbon dioxide assisted impregnation. J Pharm Biomed Anal 2008;48:1112–1119
   PubMed Web of Science ®Google Scholar
• Gong K, Braden M, Patel MP, et al. Controlled release of chlorhexidine diacetate from a porous methacrylate system: supercritical fluid assisted foaming and impregnation. J Pharm Sci 2007;96:2048–2056
   PubMed Web of Science ®Google Scholar
• Marsac PJ, Li T, Taylor LS. Estimation of drug-polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters. Pharm Res 2009;26:139–151
   PubMed Web of Science ®Google Scholar
• Gill P, Moghadam TT, Ranjbar B. Differential scanning calorimetry techniques: applications in biology and nanoscience. J Biomol Tech 2010;21:167–193
   PubMedGoogle Scholar
• Ahmed S, Sheraz MA, Yorucu C, Rehman IU. Quantitative determination of tolfenamic acid and its pharmaceutical formulation using FTIR and UV spectrometry. Cent Eur J Chem 2013;11:1533–1541
   Google Scholar
• Jabeen S, Dines TJ, Leharne SA, Chowdhry BZ. Raman and IR spectroscopic studies of fenamates – conformational differences in polymorphs of flufenamic acid, mefenamic acid and tolfenamic acid. Spectrochim Acta A Mol Biomol Spectrosc 2012;96:972–985
   PubMed Web of Science ®Google Scholar
• Doherty C, York P. Evidence for solid-state and liquidstate interactions in a furosemide polyvinylpyrrolidone solid dispersion. J Pharm Sci 1987;76:731–737
   PubMed Web of Science ®Google Scholar
• Damian F, Blaton N, Desseyn H, et al. Solid state properties of pure UC-781 and solid dispersions with polyvinylpyrrolidone (PVP K30). J Pharm Pharmacol 2001;53:1109–1116
   PubMed Web of Science ®Google Scholar
• Kestur US, Van Eerdenbrugh B, Taylor LS. Influence of polymer chemistry on crystal growth inhibition of two chemically diverse organic molecules. CrsytEngComm 2011;13:6712–6718
   Web of Science ®Google Scholar
• Volodko AV, Davydova VN, Barabanova AO, et al. Formation of soluble chitosan–carrageenan polyelectrolyte complexes. Chem Nat Compd 2012;48:353–357
   Web of Science ®Google Scholar
• Szakonyi G, Zelko R. The effect of water on the solid state characteristics of pharmaceutical excipients: molecular mechanisms, measurement techniques, and quality aspects of final dosage form. Int J Pharm Investig 2012;2:18–25
   PubMedGoogle Scholar
• Szente V, Baska F, Zelkó R, Süvegh K. Prediction of the drug release stability of different polymeric matrix tablets containing metronidazole. J Pharm Biomed Anal 2011;54:730–734
   PubMed Web of Science ®Google Scholar
• Andronis V, Zografi G. Crystal nucleation and growth of indomethacin polymorphs from the amorphous state. J Non-Cryst Solids 2000;271:236–248
   Web of Science ®Google Scholar
• Crowley KJ, Zografi G. The effect of low concentrations of molecularly dispersed poly(vinylpyrrolidone) on indomethacin crystallization from the amorphous state. Pharm Res 2003;20:1417–1422
   PubMed Web of Science ®Google Scholar